Eli Lilly's next Phase III trial is assessing whether lepodisiran can not only reduce levels of lipoprotein(a) but also ...

BMO Capital Markets analysts said the results potentially position lepodisiran as “one of the most durable assets in ...

Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein (a) levels by more than 90% for at least six ...

Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein(a) ...

Today's riddle: What do you call a giraffe in the middle of the road? 🤔 (Answer below!) Weather forecast: 🗓 Upcoming Events ...

A Kalamazoo Township police officer and a suspect were hurt after shots were fired in Kalamazoo on Thursday, according to the ...

Eli Lilly (LLY) and Company announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA, siRNA, therapy ...

CHICAGO — Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more ...